Novo, Nordisk

Novo Nordisk Faces Dual NAION Scrutiny as NovoCare Reworks the Wegovy Treatment Path

Published on 11/20/2026 at 07:31 | Editorial boerse-global.de
Danish authority approved 31 NAION compensation claims tied to Wegovy and Ozempic; FDA added warnings. Novo Nordisk relaunched NovoCare support for Wegovy users.
Novo, Nordisk, Faces, Dual, NAION, Scrutiny, NovoCare, Reworks, Wegovy, Treatment Illustration mit AI erstellt.

Novo Nordisk's semaglutide franchise is now being squeezed from two directions at once: a Danish compensation body has formally recognized 31 cases of the rare eye condition NAION linked to Wegovy and Ozempic, while the company is simultaneously trying to keep patients on treatment through a revamped support program. The two developments are unrelated in origin but converge on the same question — how durable is the Wegovy and Ozempic business?

What the Danish figure actually represents

As of November 18, Patienterstatningen, Denmark's patient compensation authority, had approved 31 claims in which people developed NAION after using Wegovy or Ozempic and were granted compensation. That is not a tally of adverse-event reports filed by doctors or patients with a medicines regulator. Each application is assessed individually and recognized only where the drug has caused the condition on the balance of probabilities. In every one of those cases, a state body has concluded from the case file that the product was more likely the cause than not — a materially different standard from statistical suspicion.

The approvals are only part of the picture. The authority has received 94 applications in total, rejecting 29 and leaving 34 undecided. Reviews clearly do not always favor claimants, but the count of recognized cases can still rise.

FDA's warning and the numbers behind it

Across the Atlantic, the FDA on November 9 required warnings on all GLP-1 products, including Ozempic and Wegovy, flagging a possibly increased NAION risk. The agency drew in part on an analysis of 126 randomized trials. Across GLP-1 agents, 6.4 cases per 100,000 person-years occurred, against 3.8 for placebo or glucose-lowering drugs outside the class.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

An FDA observational study in adults with type 2 diabetes produced a mixed picture. Against SGLT-2 inhibitors the hazard ratio was 1.19, a difference that was not statistically significant. Against DPP-4 inhibitors it was 1.43, with the full confidence interval staying above one. The data cover the entire drug class rather than semaglutide alone, the active ingredient in Novo Nordisk's products — yet the warning applies to Wegovy and Ozempic as well.

Why the immediate damage is contained

Two factors limit the near-term impact. NAION remains a rare disease even among GLP-1 users, and the Danish compensation is paid by the health ministry, not the manufacturer — though a legal recourse against the company is not ruled out. The real weight of the matter does not lie in Danish payouts. It lies in two independent bodies pointing the same way: in Denmark an authority attributes the condition to the drug case by case, and in the US the regulator considers the risk tangible enough to put it in the product information, where doctors and patients read it before deciding on treatment. NAION is therefore a serious business risk for Novo Nordisk, and a meaningful drag on Wegovy and Ozempic is a realistic possibility. What is established so far is the recognized individual cases and the FDA's risk signal — not a decline in prescriptions or added costs for the group.

NovoCare targets the everyday grind of treatment

Separately, Novo Nordisk on Tuesday relaunched its NovoCare support offering for Wegovy users. For investors, the test is whether the program eases access to treatment and helps patients stay on it; the launch alone is no signal of higher demand. It does show where the company is focusing: the practical steps surrounding an ongoing therapy.

NovoCare bundles information on treatment and reimbursement with home delivery, coaching and partner offers, and a points program is planned. Each element addresses a different hurdle — information aids orientation, delivery simplifies obtaining the drug, coaching accompanies day-to-day treatment. The Novo Nordisk share fell 2.0% on Thursday evening and is down 4.2% over seven days.

Continuation, not clicks, is the metric that matters

The economic yardstick for NovoCare would not be how many people visit the offering. It would be whether more patients continue their Wegovy treatment. Between interest in a program and an actually continued therapy lies the gap that counts for investors — a reimbursement inquiry, for instance, is not the same as a commitment to cover the cost. NovoCare therefore demands a different kind of evidence than a new drug: whether the services genuinely remove practical obstacles. Clinical data on other Novo Nordisk products cannot answer that question, however important they are for the company's broader development.

In the favorable scenario the services interlock. Patients could resolve reimbursement questions more easily and use home delivery to simplify supply. If that helps avoid interruptions, NovoCare could support Wegovy without any change to the medicine itself.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

CagriSema runs on a parallel track

Meanwhile, Novo Nordisk is advancing other treatment options. On November 14 the company reported an estimated mean weight loss of 20.7% and 21.0% for two lower-dose regimens of the investigational drug CagriSema. Placebo produced 2.0%. The 68-week analysis reflected estimated efficacy assuming participants adhered to their assigned treatment. For investors this is a separate angle: NovoCare targets the treatment routine with Wegovy, while the CagriSema study examines the effect of further dosing schedules.

The downside case and the next milestone

In the unfavorable scenario, patients use the extra information without any improvement in their ability to stay on treatment. If reimbursement remains a hurdle, more convenient delivery and coaching can pass it by — the broader offering would be more comfortable for users without meaningfully supporting Wegovy demand. Add to that the individual weighing of benefits and risks: Reuters reported that the FDA on November 9 demanded a notice on GLP-1 medicines including Wegovy and Ozempic about a possibly increased risk of the rare eye disease NAION, which can cause sudden vision loss. Everyday support cannot substitute for such medical questions.

The next announced NovoCare element is the planned points program. Should Novo Nordisk introduce it, the key question for valuation would be whether it contributes to treatment continuation beyond mere program usage; the launch itself would initially be an expansion of the offering, not proof of that effect. Until better therapy continuation can be derived from NovoCare use, an economic prop for Wegovy remains a scenario. If patients prove more likely to stay on treatment with the support, the offering would carry more weight for investors. And if reimbursement hurdles persist, even a more widely used program would on its own be no reason to raise expectations for Wegovy.

Ad

Novo Nordisk Stock: New Analysis - 20 November

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

Disclaimer...
en | DK0062498333 | NOVO | boerse | 70538793 |